The body weight-lowering effects of multi-agonists are primarily due to their anorectic actions As multi-agonist therapies elicited a marked reduction in body weight during the first week of treatment, we assessed the putative mechanisms associated with such weight loss
For CKD stages 1 and 2, protein intake usually doesnt need to be restricted
Successful discontinuation requires ensuring the lifestyle modifications around nutrition, movement, stress management, and sleep established during treatment can be sustained without medication support
In the world of antioxidants, balance is key
That timing helps align the therapy with the moments of highest metabolic demand
Your doctor may refer you to an endocrinologist or clinical genetics specialist to assess your individual risk and discuss whether GLP-1 therapy is appropriate for you